Bone Mineral Densitometry Market to Reach US$ 495.1 Million by 2034, Expanding at a 3.5% CAGR : Fact.MR Report

Bone mineral densitometry market benefitting from non-invasive design of technique suitable for mass screening programs.


Rockville, MD, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Fact.MR’s estimations place the global bone mineral densitometry (BMD) market is estimated at a value of US$ 351.2 million in 2024 and is projected to expand at a CAGR of 3.5% to reach US$ 495.1 million by the end of 2034.

Bone mineral densitometers are increasingly sought after due to their versatility and heightened recognition in medicine. These devices, pivotal for assessing bone density to gauge fracture risk and diagnose osteoporosis, are expanding their roles.

An aging global population has intensified the demand for osteoporosis screening. Additionally, densitometers now serve diverse fields like sports medicine, pediatrics, and even space exploration. They play a crucial role in monitoring bone disease treatments and evaluating bone health in cancer patients. Their non-invasive nature and minimal radiation exposure make them ideal for widespread screening initiatives. Furthermore, their ability to assess body composition has found application in fitness and nutrition. As awareness of bone health grows and densitometry finds new applications, the BMD market is poised for continuous expansion.

For More Insights into the Market, Request a Sample of this Report-https://www.factmr.com/connectus/sample?flag=S&rep_id=10230

Key Takeaways from Market Study

  • The global bone mineral densitometry market is projected to reach a size of US$ 495.1 million by the end of 2034.
  • East Asia is evaluated to account for 5% share of the global market by 2034-end.
  • The market in North America is forecasted to reach a valuation of US$ 184 million by 2034.
  • By 2034, the BMD market in Canada is evaluated to reach US$ 18 million.
  • Based on technology, sales of DXA devices are estimated at US$ 225.9 million in 2024.
  • Based on end users, the hospitals segment is expected to account for a market share of 5% in 2024.

“Increasing global incidence of osteoporosis and bone-related disorders are driving demand for bone mineral densitometry devices. Shifts towards an older population demographic, particularly postmenopausal women, who are at higher risk of osteoporosis and fractures is driving bone mineral densitometry market growth,” says a Fact.MR analyst.

Leading Players Driving Innovation in the Bone Mineral Densitometry Market:

GE Healthcare Hologic Inc.; DMS Imaging; Swissray International Inc.; Xingaoyi Medical Equipment Co. Ltd.; Eurotec Medical Systems; Trivitron Healthcare AB; Medonica Co. Ltd.; Diagnostic Medical Systems Group.

REMS Technique and 3D Imaging Clinical Offering Efficiency and Patient Comfort Enhancement

Enhancing clinical efficiency and patient comfort is paramount. Nowadays, various devices with 3D imaging capabilities provide a comprehensive view of bone quality and structure, surpassing mere density assessments. Portable and mobile technologies are enhancing access to bone health screening, particularly for bedridden individuals and those in remote areas. Simultaneously, integration with electronic health records is streamlining workflows and enabling continuous patient monitoring.

Emerging technologies like radiofrequency echographic multi-spectrometry (REMS) are advancing, offering radiation-free alternatives to traditional DXA scans. Moreover, algorithmic advancements are creating opportunities for opportunistic bone health screening through routine CT scans.

Bone Mineral Densitometry Industry News:

  • SOPHiA Genetics, a cloud-native software provider for the healthcare industry, announced in February 2023 that Synergy Laboratories, an Alabama full-service diagnostic laboratory, will now utilize SOPHiA DDM to provide sophisticated cancer profiling solutions. Synergy Laboratories intends to use this cutting-edge platform for cancer research and clinical trials to broaden the scope of its offerings.
  • The United States Food and Drug Administration (FDA) announced in December 2022 that Mirati Therapeutics, a commercial-stage biotechnology firm, received a Breakthrough Therapy Designation (BTD) for adagrasib with cetuximab. This shows a potential therapeutic action for individuals with advanced colorectal cancer that has a mutation in the KRAS gene.

Get Customization on this Report for Specific Research Solutions-https://www.factmr.com/connectus/sample?flag=S&rep_id=10230

More Valuable Insights on Offer

Fact.MR, in its new offering, presents an unbiased analysis of the bone mineral densitometry (BMD) market for 2019 to 2023 and forecast statistics for 2024 to 2034.

The study divulges essential insights into the market based on product (axial bone densitometers, peripheral bone densitometers), technology (dual-energy X-ray absorptiometry, peripheral dual-energy X-ray absorptiometry, quantitative ultrasound), and end user (hospitals, orthopedic clinics, diagnostic centers), across seven major regions of the world (North America, Latin America, Western Europe, Eastern Europe, East Asia, South Asia & Pacific, and MEA).

Checkout More Related Studies Published by Fact.MR Research: 

The global bone and joint health supplement market has been valued at US$ 34.89 billion in 2024. Worldwide sales of bone and joint health supplements are projected to climb at a CAGR of 7.5% and reach US$ 71.91 billion by the end of 2034.

The global bone biopsy systems market is set to enjoy a valuation of US$ 227.6 million in 2022 and expand at a CAGR of 6% to reach US$ 408.9 million by the end of 2032.

The global bone cement & glue market is predicted to rise at a CAGR of 5.4% and increase from a market valuation of US$ 1.3 billion in 2022 to US$ 2.2 billion by the end of 2032. Demand for bone cement is forecasted to increase faster at a CAGR of 6.2% through 2032

The global bone glue market size is estimated at a value of US$ 1.03 billion in 2024, as per a new research published by Fact.MR. Worldwide sales of bone glue are forecasted to rise at 7.2% CAGR and reach US$ 2.07 billion by the end of 2034.

The global bone grafts and substitutes market reached a valuation of US$ 3.06 Billion in 2020. Sales of bone grafts and substitutes are slated to rise at a CAGR of 4.9% to reach US$ 4.44 Billion by the end of 2028.

The global bone growth stimulator market was valued at US$ 1.89 Billion in 2021. By 2022, the market is expected to touch a valuation of US$ 1.99 Billion, exhibiting a Y-o-Y increase of 5.3%. During the forecast period of 2022-2032,

About Us: 

Fact.MR is a distinguished market research company renowned for its comprehensive market reports and invaluable business insights. As a prominent player in business intelligence, we deliver deep analysis, uncovering market trends, growth paths, and competitive landscapes. Renowned for its commitment to accuracy and reliability, we empower businesses with crucial data and strategic recommendations, facilitating informed decision-making and enhancing market positioning. With its unwavering dedication to providing reliable market intelligence, FACT.MR continues to assist companies in navigating dynamic market challenges with confidence and achieving long-term success. With a global presence and a team of experienced analysts, FACT.MR ensures its clients receive actionable insights to capitalize on emerging opportunities and stay ahead in the competitive landscape.  

Follow Us:LinkedIn | Twitter | Blog 

 

Contact Data